Latest Close
₹2,376.10
+1.01%
Connecting…
Day Range
-
Full OHLC pending
Volume
-
Full session data pending
50 DMA
₹2,626.52
200 DMA
₹2,123.50
1 year gain / loss
+₹345.60(+17.02%)
₹2,030.50 → ₹2,376.10· 2025-10-30 to 2026-10-30
Charting by TradingView
This stock does not satisfy the default swing-support rules at the selected chart endpoint. Its price, volume and moving averages remain available for manual research.
Snapshot 2026-11-01 · Financial period Jun 2026 · Consolidated figures where available
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Market Cap
₹17,671.58 Cr
P/E
26.06×
Sector -38.72× · above
P/B
5.24×
Sector 4.11× · above
EV / EBITDA
18.49×
Sector 19.14× · below
ROE
17.88%
Sector 0.37%
ROCE
22.30%
Sector 6.55%
ROA
16.76%
Sector -17.04%
Cash Flow / Profit
0.81×
| Period | Revenue | Operating profit | Net profit |
|---|---|---|---|
| Jun 2026 | 643.91 +2.5% | 225.22 | 179.09 +3.6% |
| Mar 2026 | 628.52 +9.0% | 213.44 | 172.88 +4.2% |
| Dec 2025 | 576.45 +2.1% | 203.89 | 165.86 +3.5% |
| Sep 2025 | 564.41 | 201 | 160.23 |
Dividend
18 Sep 2026 · ₹4
Dividend
29 May 2026 · ₹4